RA Capital has already participated in four biotech financings in September. Meanwhile, Janus Henderson has been the year's most prolific backer of biotech reverse merger deals, according to Gilmartin ...

Karyopharm bought an extra month to negotiate with creditors or pursue a deal. Elsewhere, BridgeBio Pharma’s oncology spinout shook up its development plans and a brain-focused gene therapy startup ...

Once disparaged, reverse mergers have become so popular that some deal experts question whether there are enough quality ...

Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines.

Announced mere weeks after Biohaven sold off rights to the therapy, opakalim, the halt affects a study some analysts believe is necessary to support a potential approval.

One analyst views Roivant’s pulmonary hypertension drug as a future $10 billion-plus seller. Elsewhere, AstraZeneca overcame a negative advisory committee vote and Pharvaris claimed success in a key ...

AI is evolving from interactive chats to automated workloads driven by agentic tools, compressing timelines and enabling faster outcomes. A new reference architecture running on the Dell Pro Max with ...

Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of ...

Plump joined Takeda during a turbulent period, pushed the company to work more closely with young biotechs and will leave it ...

The failure of what was once considered a potential blockbuster therapy represents a major setback in a tough-to-treat ...

The failure of “del-desiran,” which Novartis got through a $12 billion acquisition, could raise questions about the company’s ...

Pelacarsen didn’t protect heart health despite lowering levels of a protein particle, “Lp(a),” in a large clinical trial — a ...